Trade Summary

5 days ago, Third Rock Ventures V, L.P., serving as 10% owner at Rapport Therapeutics, Inc. (RAPP), sold 426,005 shares at $40.32 per share, for a total transaction value of $17,175,244.00. Following this transaction, Third Rock Ventures V, L.P. now holds 7,678,446 shares of RAPP.

This sale represents a 5.00% decrease in Third Rock Ventures V, L.P.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, April 17, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, April 21, 2026, 4 days after the trade was made.

Rapport Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.